GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more
GeneMatrix Inc - Asset Resilience Ratio
GeneMatrix Inc (109820) has an Asset Resilience Ratio of 41.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how GeneMatrix Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down GeneMatrix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩11.64 Billion | 41.52% |
| Total Liquid Assets | ₩11.64 Billion | 41.52% |
Asset Resilience Insights
- Very High Liquidity: GeneMatrix Inc maintains exceptional liquid asset reserves at 41.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GeneMatrix Inc Industry Peers by Asset Resilience Ratio
Compare GeneMatrix Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
Annual Asset Resilience Ratio for GeneMatrix Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for GeneMatrix Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.41% | ₩1.82 Billion | ₩28.46 Billion | -0.39pp |
| 2023-12-31 | 6.80% | ₩2.13 Billion | ₩31.35 Billion | -8.23pp |
| 2022-12-31 | 15.03% | ₩4.79 Billion | ₩31.90 Billion | -16.53pp |
| 2021-12-31 | 31.55% | ₩12.47 Billion | ₩39.53 Billion | -0.42pp |
| 2020-12-31 | 31.97% | ₩12.20 Billion | ₩38.17 Billion | +0.43pp |
| 2019-12-31 | 31.54% | ₩8.97 Billion | ₩28.46 Billion | -16.84pp |
| 2018-12-31 | 48.38% | ₩15.25 Billion | ₩31.52 Billion | +5.25pp |
| 2017-12-31 | 43.13% | ₩7.65 Billion | ₩17.74 Billion | -6.16pp |
| 2016-12-31 | 49.29% | ₩9.53 Billion | ₩19.33 Billion | +18.97pp |
| 2015-12-31 | 30.31% | ₩6.30 Billion | ₩20.78 Billion | +8.02pp |
| 2014-12-31 | 22.30% | ₩3.80 Billion | ₩17.05 Billion | +3.29pp |
| 2013-12-31 | 19.00% | ₩3.74 Billion | ₩19.68 Billion | +1.01pp |
| 2012-12-31 | 18.00% | ₩3.66 Billion | ₩20.35 Billion | +1.73pp |
| 2011-12-31 | 16.27% | ₩3.68 Billion | ₩22.62 Billion | -- |